SLC5A2 and type 2 diabetes mellitus: This supports the early use of SGLT2 inhibitors as part of an integral approach to T2DM management, particularly in overweight or obese patients at higher risk of disease progression, emphasizing the role of empagliflozin in patients without documented high cardiovascular risk [23,26].